Pulse.

a daily field guide to health research that matters

◆ Console

‹ Tue · 10 Nov 2026
Promising but preliminary

Tumor-Informed Circulating Tumor DNA Monitoring for Predicting Outcomes in Patients With Head and Neck Squamous Cell Carcinoma.

Detecting circulating tumor DNA after head-and-neck cancer treatment predicts which patients face higher recurrence risk.

Here, we evaluated circulating tumor DNA (ctDNA) testing post-definitive treatment to detect molecular residual disease (MRD) and predict outcomes in patients with HNSCC. In patients with stage I to IV HNSCC, ctDNA-based MRD positivity after definitive local therapy and adjuvant treatment is associated with disease recurrence and poor survival outcomes.

What the study was

Study design
Journal article (design unspecified)
Category
Early Detection
Maturity
Validated
Journal
Advances in radiation oncology

Why it surfaced

⚪ PROMISING_PRELIMINARY — Promising but preliminary; Watchlist: Early cancer detection (liquid biopsy, ctDNA, cfDNA); Design: Journal article (design unspecified); species: human

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.